TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced a contractual agreement with AppTec, headquartered in St. Paul, Minnesota, for the preclinical testing of its lead product.

The immunotherapy vaccine is designed to treat a wide variety of carcinomas that include lung cancers, liver cancers, kidney cancers, head and neck cancers, breast cancers, melanomas, prostate cancers, colorectal cancers, and cervical cancers. This is the first stage in moving the company's proprietary vaccine from the research laboratory into clinical investigation.

Once AppTec certifies the vaccine as sterile and free of contamination, TapImmune will move forward with the production of commercial grade vaccine in FDA approved facilities to commence pre-clinical work, toxicology and phase I clinical trials

"This partnership signifies the first step on our clinical critical path," said Denis Corin, CEO and president of TapImmune Inc. "Moving our product from the research laboratory and into FDA regulated facilities for testing signifies our commitment to advance this research and bring to market a product which we believe will have a significant impact on the battle against cancer."

"AppTec is very pleased that TapImmune has chosen to partner with us in this next phase of development for their new vaccine," said Bonnie Baskin, CEO of AppTec, "and we are excited to play a role in helping to advance such an important product closer to market."

AppTec offers comprehensive testing, contract research and development, and cGMP manufacturing services for biopharmaceuticals, medical devices, cellular therapeutics and tissue-based products from a unique single-source platform.

TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, the AdhTAP vaccine restores and augments antigen presentation and subsequent recognition and killing of cancer cells by the immune system.